Bristol Myers Squibb Receives FDA Approval for Breyanzi CAR-T in Follicular Lymphoma

Bristol Myers Squibb today announced that the FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of therapy. In the Phase 2 TRANSCEND FL trial, Breyanzi demonstrated a complete response rate of 94% with a median duration of response not yet reached. This approval expands Breyanzi's indications to include follicular lymphoma and provides a potentially curative treatment option for patients with this indolent B-cell lymphoma.